Scientia pro bono humani generis: Science for the benefit of humanity

doi:10.1017/cts.2023.696

Editorial

. 2024 Feb 20;8(1):e29.

doi: 10.1017/cts.2023.696. eCollection 2024.

Scientia pro bono humani generis: Science for the benefit of humanity

Laura P James¹, Robert Kimberly², Christopher John Lindsell³, Jareen K Meinzen-Derr⁴, Ruth O'Hara⁵

Affiliations

¹ University of Arkansas for Medical Sciences (UAMS) and Arkansas Children's Hospital, Little Rock, AR, USA.
² University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.
³ Data Science and Biostatistics, Duke University, Duke Clinical Research Institute, Durham, NC, USA.
⁴ Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Center for Clinical and Translational Science and Training, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
⁵ Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.

PMID: 38384907
PMCID: PMC10879989
DOI: 10.1017/cts.2023.696

Editorial

Scientia pro bono humani generis: Science for the benefit of humanity

Laura P James et al. J Clin Transl Sci. 2024.

. 2024 Feb 20;8(1):e29.

doi: 10.1017/cts.2023.696. eCollection 2024.

Authors

Laura P James¹, Robert Kimberly², Christopher John Lindsell³, Jareen K Meinzen-Derr⁴, Ruth O'Hara⁵

Affiliations

¹ University of Arkansas for Medical Sciences (UAMS) and Arkansas Children's Hospital, Little Rock, AR, USA.
² University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.
³ Data Science and Biostatistics, Duke University, Duke Clinical Research Institute, Durham, NC, USA.
⁴ Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Center for Clinical and Translational Science and Training, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
⁵ Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.

PMID: 38384907
PMCID: PMC10879989
DOI: 10.1017/cts.2023.696

No abstract available

PubMed Disclaimer

Conflict of interest statement

None.

Cited by

Insights from the trial innovation network's initial consultation process.
Harris PA, Kennedy N, Wilkins CH, Lane K, Bernard GR, Casey JD, Ford DE, Waddy SP, Wiley KL Jr, Edwards TL, McBee N, Thompson DD, Stroud M, Serdoz ES, Nelson SJ, Jones M, Eyzaguirre LM, Boone LR, Baird J, Lawrence CE, Holthouse E, Cook SK, Tischbein M, Amrine N, Chen T, Cohen J, Deyampert L, Dilts NA, Burts D, Baig A, Christodoulou JG, Rodriguez M, Miller ER 3rd, Casella JF, Mould WA, Dean JM, Benjamin DK, Selker HP, Palm ME, Poole L, Burr JS, Hassani S, Nanni A, Hildreth M, Hanley DF. Harris PA, et al. J Clin Transl Sci. 2025 Jun 26;9(1):e149. doi: 10.1017/cts.2025.10084. eCollection 2025. J Clin Transl Sci. 2025. PMID: 40735123 Free PMC article.

References

1. World Health Organization. Clinical trials. https://www.who.int/health-topics/clinical-trials#tab=tab_1. Accessed November 3, 2023.
1. Zarin D, Goodman S, Kimmelman J. Harms from uninformative clinical trials. JAMA. 2019;322(9):813–814. - PubMed
1. Bugin K, Woodcock J. Trends in COVID-19 therapeutic clinical trials. Nat Rev Drug Discov. 2021;20(4):254–255. - PubMed
1. Hutchinson N, Moyer H, Zarin D, Kimmelman J. The proportion of randomized controlled trials that inform clinical practice. eLife. 2022;11:379491. - PMC - PubMed
1. Kost RG, Devine RK, Fernands M, et al. Building an infrastructure to support the development, conduct, and reporting of informative clinical studies: the rockefeller university experience. J Clin Transl Sci. 2023;7(1):1–12. doi: 10.1017/cts.2023.521. - DOI - PMC - PubMed

Publication types

Actions

Grants and funding

UL1 TR003142/TR/NCATS NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central

[1] World Health Organization. Clinical trials. https://www.who.int/health-topics/clinical-trials#tab=tab_1. Accessed November 3, 2023.

[2] World Health Organization. Clinical trials. https://www.who.int/health-topics/clinical-trials#tab=tab_1. Accessed November 3, 2023.

[3] Zarin D, Goodman S, Kimmelman J. Harms from uninformative clinical trials. JAMA. 2019;322(9):813–814. - PubMed

[4] Zarin D, Goodman S, Kimmelman J. Harms from uninformative clinical trials. JAMA. 2019;322(9):813–814. - PubMed

[5] Bugin K, Woodcock J. Trends in COVID-19 therapeutic clinical trials. Nat Rev Drug Discov. 2021;20(4):254–255. - PubMed

[6] Bugin K, Woodcock J. Trends in COVID-19 therapeutic clinical trials. Nat Rev Drug Discov. 2021;20(4):254–255. - PubMed

[7] Hutchinson N, Moyer H, Zarin D, Kimmelman J. The proportion of randomized controlled trials that inform clinical practice. eLife. 2022;11:379491. - PMC - PubMed

[8] Hutchinson N, Moyer H, Zarin D, Kimmelman J. The proportion of randomized controlled trials that inform clinical practice. eLife. 2022;11:379491. - PMC - PubMed

[9] Kost RG, Devine RK, Fernands M, et al. Building an infrastructure to support the development, conduct, and reporting of informative clinical studies: the rockefeller university experience. J Clin Transl Sci. 2023;7(1):1–12. doi: 10.1017/cts.2023.521. - DOI - PMC - PubMed

[10] Kost RG, Devine RK, Fernands M, et al. Building an infrastructure to support the development, conduct, and reporting of informative clinical studies: the rockefeller university experience. J Clin Transl Sci. 2023;7(1):1–12. doi: 10.1017/cts.2023.521. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Scientia pro bono humani generis: Science for the benefit of humanity

Affiliations

Scientia pro bono humani generis: Science for the benefit of humanity

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources